๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study

โœ Scribed by Deborah K. Armstrong; John A. Blessing; Katherine Y. Look; Russell Schilder; Evelyn R. Nunez

Book ID
111551133
Publisher
Springer US
Year
2003
Tongue
English
Weight
62 KB
Volume
21
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II evaluation of three-day topotec
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study
โœ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a